RT Journal Article
SR Electronic
T1 Genomic profiling reveals heterogeneous populations of ductal carcinoma in situ of the breast
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.22.20137018
DO 10.1101/2020.06.22.20137018
A1 Satoi Nagasawa
A1 Yuta Kuze
A1 Ichiro Maeda
A1 Yasuyuki Kojima
A1 Ai Motoyoshi
A1 Tatsuya Onishi
A1 Tsuguo Iwatani
A1 Takamichi Yokoe
A1 Junki Koike
A1 Motohiro Chosokabe
A1 Manabu Kubota
A1 Hibiki Seino
A1 Ayako Suzuki
A1 Masahide Seki
A1 Katsuya Tsuchihara
A1 Eisuke Inoue
A1 Koichiro Tsugawa
A1 Tomohiko Ohta
A1 Yutaka Suzuki
YR 2020
UL http://medrxiv.org/content/early/2020/06/25/2020.06.22.20137018.abstract
AB A substantial number of cases of ductal carcinoma in situ (DCIS) of the breast will never progress to invasive ductal carcinoma (IDC), indicating they are overtreated under the current criteria. Although various candidate markers are available, the relevant markers for delineating the risk categories have not been established. In this study, we analyzed of the integrated clinical features of 431 cases of DCIS followed by deep sequence analyses in a 21-case discovery cohort and a 72-case validation cohort. We identified the five most critical markers of the aggressiveness of DCIS: age <45 years, HER2 amplification, GATA3 mutation positivity, PIK3CA mutation negativity, and PgR protein negativity. Spatial transcriptome and single-cell DNA sequencing further revealed that GATA3 dysfunction, but not PIK3CA mutation, upregulates EMT, invasion, and angiogenic pathways followed by PgR downregulation. These results reveal the existence of heterogeneous populations of DCIS and provide predictive markers for classifying DCIS and optimizing treatment.Competing Interest StatementThe authors have declared no competing interest.Funding Statementno external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved (approval number: 2297-i103) by the Clinical Ethics Committee of St. Marianna University, and a waiver of consent was granted for the use of archival clinical samples from the Department of Pathology.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll sequencing data and pathological images for STseq have been deposited in the DNA Data Bank of Japan under the accession number JGAS00000000202.